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Abstract
Acid-sensing ion channels (ASICs) are proton-gated cation channels that are predominantly
expressed in the nervous system. ASICs are involved in a number of neurological diseases such as
pain, ischemic stroke and multiple sclerosis but limited tools are available to target these channels
and provide probes for their physiological functions. Here we report that the anti-protozoal
diarylamidines, 4′,6-diamidino-2-phenylindole (DAPI), diminazene, hydroxystilbamidine (HSB)
and pentamidine potently inhibit ASIC currents in primary cultured hippocampal neurons with
apparent affinities of 2.8 µM, 0.3 µM, 1.5 µM and 38 µM, respectively. These four compounds
(100 µM) failed to block ENaC channels expressed in oocytes. Sub-maximal concentrations of
diminazene also strongly accelerated desensitization of ASIC currents in hippocampal neurons.
Diminazene blocked ASIC1a, -1b -2a, and -3 currents expressed in CHO cells with a rank order of
potency 1b > 3 > 2a ≥ 1a. Patchdock computational analysis suggested a binding site of
diarylamidines on ASICs. This study indicates diarylamidines constitute a novel class of nonamiloride ASIC blockers and suggests that diarylamidines may be developed as therapeutic agents
in treatment of ASIC-involved diseases.
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1. Introduction
ASICs represent a 6-member (ASIC1a, -1b, -2a, -2b, -3 and -4) subgroup of the degenerin/
epithelial sodium channel (DEG/ENaC) family of cation channels (Grunder et al., 2000;
Waldmann et al., 1997; Wemmie et al., 2006) and they are widely expressed in sensory
neurons of the dorsal root ganglion (DRG) and in the neurons of the brain (Lingueglia,
2007; Xiong et al., 2008). The crystal structures of chicken ASIC1 have been resolved
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(Gonzales et al., 2009; Jasti et al., 2007). These channels are implicated in a wide spectrum
of neuronal functions including synaptic plasticity, mechanosensation and modulation of
retinal function (Krishtal, 2003; Wemmie et al., 2006). However, the normal physiological
functions of ASIC remain not fully understood, partly due to the lack of good
pharmacological tools for their study.
In contrast, ASICs have been extensively studied for their pathophysiological roles. ASICs
contribute to several disease states. For example, activation of ASIC1a expressed in
interneurons is thought to facilitate termination of epileptic seizure when pH falls (Ziemann
et al., 2008). ASIC1a is also associated with axonal degeneration in the experimental
autoimmune encephalomyelitis (EAE) model (Friese et al., 2007) and contributes to focal
ischemic brain injury (Xiong et al., 2004). In peripheral neurons ASICs are widely believed
to mediate acid-induced pain or to act as sensors of inflammatory pain (Deval et al., 2008).
ASIC inhibitors attenuate peripheral acid-induced hyperalgesia in rats (Dube et al., 2005) as
well as pain in human subjects (Ugawa et al., 2002).
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There are few ASIC inhibitors available to probe their function in vivo or to intervene in
ASIC-associated diseases. Two poly-peptide toxins were identified as modulators of ASIC
activity (Chen et al., 2005; Diochot et al., 2004; Escoubas et al., 2000) and several small
molecules, in addition to the diuretic amiloride and derivatives (Kuduk et al., 2009a,b), have
been reported to inhibit ASIC currents. Some non-steroidal anti-inflammatory drugs inhibit
ASICs (Voilley et al., 2001). A-317567 and nafamostat mesilate also block native ASIC
currents in dorsal root ganglion (DRG) neurons and oocyte-expressing ASICs (Dube et al.,
2005; Ugawa et al., 2007) but do so with relatively low potency.
Here we report that a class of anti-protozoan diarylamidines including diminazene, DAPI,
HSB, and pentamidine inhibit ASIC currents in cultured hippocampal neurons with
relatively high affinity. They also attenuate the excitation of these neurons in response to an
acid challenge. Moreover, diminazene dramatically enhances the rate of desensitization of
ASIC currents. Based on structural–functional analysis of diarylamidines, their analogs, and
ASICs, we mapped out a common molecular template for designing potent blockers for
ASICs. This novel class of ASIC blockers might be useful for ASIC functional study and be
of therapeutic significance for intervention in ASIC-related disorders such as chronic pain.

2. Methods
2.1. Cell culture
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All animal experiments were carried out according to guidelines approved by the University
of Toronto Animal Care Committee. Primary cultures of mouse hippocampal and cortical
neurons were prepared as previously described (Wei et al., 2007). Briefly, cultures of
hippocampal neurons were prepared from Swiss mice. Pregnant mice were sacrificed by
cervical dislocation under anesthesia (isoflurane) and fetuses were rapidly removed at
embryonic day E17–18. Hippocampal tissues were dissected and placed in cold Hanks'
solution prior to dissociation. Hippocampal neurons were dissociated by mechanical
trituration and plated on 35 mm culture dishes at an estimated density of <1 × 106 cells/cm2.
Cell cultures were incubated in a minimal essential media supplemented with 10% fetal
bovine serum, 10% inactivated horse serum and insulin (8 µg/ml) at 37 °C in 5% carbon
dioxide for the first week (all chemicals from Invitrogen, Carlsbad, CA, USA). Fibroblast/
glial cell proliferation was terminated by the addition of floxuridine at day 7 in vitro.
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Electrophysiological recordings were performed on primarily cultured mouse hippocampal
neurons 14–22 days after plating. The extracellular solution was composed of (mM) 140
NaCl, 2 CaCl2, 1 MgCl2 25 N-2-Hydroxyethylpiperazine-N′-thanesulfonic acid (HEPES),
33 glucose, 5.4 KCl and 0.0002 Tetrodotoxin with pH of 7.3–7.4 and osmolarity ranging
from 320 to 330 mOsm. The intracellular solution for voltage clamp recording consisted of
(mM) 140 CsF, 11 Ethyleneglycol-bis-(α-amino-ethyl ether) N,N′-tetra-acetic acid (EGTA)
as intracellular calcium chelating buffer, 10 HEPES, 2 MgCl2, 2 Tetraethyl ammonium
chloride (TEA-Cl),1 CaCl2, and 4 K2ATP with pH adjusted by CsOH. For current-clamp
recording the pipette solution contained (inmM): 140 KCl, 5 NaCl,10 HEPES, 5 EGTA, 2
MgCl22K2ATP, pH was adjusted by KOH. Pipette resistance ranges 2–4MΩ. Recordings
were performed at room temperature. The membrane potential was held at −60 mV
throughout the recordings unless otherwise indicated. Access resistance was monitored by
applying a voltage step of −5 mV. ASIC mediated currents were elicited by rapid application
of pH 5.8 (low pH buffer, 2-N-morpholino-ethanesulfonic acid (MES) replacing HEPES)
delivered from a multi-barrel fast perfusion system for 5 s in every minute. The solution
perfusion rate was approximately 1 ml per minute. Whole-cell currents were recorded using
an Axopatch-1D amplifier (Molecular Devices, Sunnyvale, CA). Electrophysiological data
were filtered at 2 kHz and digitized at 5–10 kHz using a Digidata 1332A or/and
simultaneously through MiniDigi 1A, and acquired online with pClamp8.2 (Axon
Instruments) or/and Axoscope9.2 (Axon instruments).
2.3. Transfection of Chinese hamster ovary cells (CHO) and electrophysiological recording
Transfection of CHO cells was performed as described previously (Chu et al., 2004),
Briefly, CHO cells were cultured in F12 medium (American Type Culture Collection,
Manassas, VA) supplemented with 10% fetal bovine serum. At ~50% confluence, cells were
cotransfected with DNA for various ASICs and for green fluorescent protein (GFP) in the
pcDNA3 vector (Invitrogen, San Diego, CA), using Fugene 6 transfection reagent (Roche
Diagnostics, Indianapolis, IN). For each 35 × 35 mm culture dish, 1.8 µg of cDNA for
individual ASIC and 0.2 µg ofDNA for GFP were used. All recordings were made 48–72 h
after plating. GFP-positive cells were viewed under a fluorescence microscope for patchclamp recording. For all ASIC subunits, a holding potential of −60 mV was used. Low pH
values close to pH50 of individual ASIC subunits (e.g. 6.0 for ASIC1a and 1b, 5.0 for
ASIC2a, and 6.5 for ASIC3) were used to activate the ASIC currents.
2.4. Electrophysiology using two-electrode voltage clamp
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Experimental procedures for whole oocyte electrophysiology have been previously
described (Babini et al., 2003; Paukert et al., 2004). Ovaries of adult Xenopus laevis females
were surgically removed under anesthesia. The follicular membrane was removed by
digestion with collagenase type II (Sigma; 1 mg ml−1) for 60–120 min. Capped cRNAs of
ENaC subunits were synthesized by SP6 RNA polymerase from cDNA of ENaC alpha, beta and -gamma subunits using the mMessage mMachine kit (Ambion). 1 ng of cRNA of
EnaC was injected into stage V–VI oocytes of X. laevis. Oocytes were kept in a low Na+
oocyte ringer-2 medium (5 mm NaCl, 77.5 mm N-methyl-D-glucamine, 1 mm Na2HPO4, 2.5
mm KCl, 5 mm HEPES, 0.5 g/l polyvinylpyrrolidone, 1 mm MgCl2, and 1 mm CaCl2) at 19
°C for 3 days. During recording, oocytes were superfused with ringer solution containing
140 mm NaCl, 2.5 mm KCl, 1.8 mm CaCl2, 1 mM MgCl2 and 10 mm HEPES (pH 7.4).
Amiloride-sensitive current was measured using two-electrode voltage clamp. To determine
the effect of diarylamidines on ENaC activities, oocytes were superfused first with a
solution containing 10 µm amiloride, which was then replaced with solutions containing 0
µm amiloride. Diarylamidines (100 µM) were applied at the absence of amiloride. Whole
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oocyte amiloride-sensitive currents were recorded at 1 kHz with a TurboTec 03X amplifier
(npi electronic). Solutions were applied by means of a fast, automated perfusion system
(Screening tool, npi electronic). Holding potential was −70 mV and all experiments were
performed at room temperature (22–26 °C). Data acquisition was managed using the
software CellWorks 5.1.1 (npi electronic).
2.5. Docking diarylamidines onto ASIC1 crystal structures
The crystal structure of cASIC1 was obtained from Protein Data Band code 3HGC
(Gonzales et al., 2009) or from 2QTS (Jasti et al., 2007) as a comparison. The structures of 4
novel blockers (diminazene, DAPI, hydroxystilbamidine, pentamidine) as well as
nafamostat were downloaded from PDB bank. Rather than perform homology modeling of
rat ASIC based on cASIC1 crystals in advance, we directly docked these chemicals into
cASIC1 crystals (3HGC) to minimize possible distortion or miscalculation derived from
homology modeling. We uploaded structures of ASIC1 (structure of a single subunit and
complete trimeric channel, respectively) and blockers onto the Patchdock server (http://
bioinfo3d.cs.tau.ac.il/PatchDock/). Docking was performed by the server between cASIC1
and each of the blockers in turn and docking results with various possibility scores were sent
back via email. We chose and analyzed only docking results with high scores. Docked
structures were visualized and rendered using Pymol (www.pymol.org).
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2.6. Data analysis and chemicals
Data were analyzed with Clampfit 9.2. (Axon Instruments), Excel 2002 (Microsoft
Corporation), Origin 5.0 (Microcal Software) and illustrated using CorelDraw13 (Corel
Corporation). Currents were normalized to the amplitude of control responses. Inhibitory
concentration–response plots were fitted to the logistic equation: I = (Amax − A0)/[1+(X/
IC50)n] + A0, where I is the normalized current amplitude, X was the antagonist
concentration; n is Hill coefficient; IC50 is the concentration of antagonist that generate 50%
of maximal inhibition. All data points were expressed as mean ± S.E.M. Paired Student's t
test was used to examine the statistical significance of the difference between groups of data.
The criterion of significance was set at p < 0.05.
Structures presented in figures were re-drawn based on the structures from Pubchem (http://
www.ncbi.nlm.nih.gov/sites/entrez). Diminazene, pentamidine, gabexate, DAPI, HSB were
purchased from Sigma–Aldrich (Oakville, ON, Canada). Synthalin was from BioMol
(Plymouth meeting, PA, USA).

3. Results
NIH-PA Author Manuscript

3.1. Identification of ASIC blockers
To identify novel ASIC inhibitors, we performed a small scale screening. As the ectodomain
of ASICs contain around 80 charged amino acids (about half of them are conserved) among
total ~ 360 amino acids (Paukert et al., 2008), we hypothesized that poly- or bi-charged
chemicals are likely to bind to ASIC channels. We first tested suramin, a poly-anion, but
suramin (500 µM) failed to inhibit ASIC currents in cultured hippocampal neurons. Next we
examined bi-charged compounds. We tested if a negatively charged di-anion can modulate
ASICs currents. Carbenoxolone, a blocker of pannexin, is such a di-anion. However, at 200
µM it also failed to inhibit ASICs (Fig. 1A). Then we assessed positively charged netropsin
and synthalin, linear diguaninines, for their effects on ASIC currents. Synthalin (200 µM)
weakly inhibited ASIC currents by 29 ± 3% (n = 6, Fig. 1B) whilst netropsin was without
effect. As synthalin is a positively charged molecule, we then tested if diamidines, which
share comparable size and similar charge pattern as diguanidines, might have similar actions
on ASICs. We first studied imidocarb, a derivative from amicarbalide that is a diamidine
Neuropharmacology. Author manuscript; available in PMC 2013 December 03.
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(Wilson et al., 2005). Imidocarb (200 µM) which weakly inhibited 42 ± 7% (n = 5) ASIC
currents (Fig. 1D), has two positive charges that are not freely movable at its ends.
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3.2. Diarylamidines potently and reversibly inhibits ASIC currents
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Next we determined if the anti-protozoal agents, the diary-lamidines, inhibit ASIC currents
in cultured hippocampal neurons. Diarylamidines are a large family of biochemically and
pharmacologically interesting synthetic compounds which includes DAPI, HSB,
pentamidine, diminazene etc.(Baraldi et al., 2004). Indeed, we found that these
diarylamidines strongly inhibited ASIC currents. Fig. 2 shows that HSB inhibited ASIC
currents in hippocampal neurons with an IC50 of 1.5 ± 0.6 µM (n = 5). Pentamidine inhibited
ASIC with an IC50 of 38 ± 11 µM (n = 4) and DAPI inhibited with an IC50 of 2.8 ± 0.7 µM
(n = 4). Fig. 3 shows that diminazene potently blocked ASIC channels in cultured
hippocampal neurons with a potency of 0.29 ± 0.11 µM (n = 6). Diminazene is the most
potent small-molecular inhibitor of ASIC known so far. In addition to the reduction of
current amplitude, sub-maximal concentrations of diminazene also facilitated the rate of
desensitization of ASIC currents. Fig. 3B shows that co-application of diminazene (3 µM)
with pH 5.8 solution drastically (p < 0.01) reduced the desensitization time constant of ASIC
currents from 1.6 ± 0.3 s to 0.4 ± 0.1 s (n = 6). This suggests that diminazene may promote
the closure of ASIC channels. In contrast, sub-maximal concentrations of HSB, pentamidine
and DAPI did not have marked effects on rates of desensitization of ASIC currents (not
shown).
We also compared the effects of diminazene on ASIC desensitization with sub-maximal
concentration of amiloride. Amiloride is an open channel blocker of ASICs (Paukert et al.,
2004). The IC50 of amiloride on ASIC current is reported to be 10–20 µM (Waldmann et al.,
1997; Wu et al., 2004) but up to 200–500 µM amiloride is required to completely block the
neuronal ASIC currents (Baron et al., 2002; Wu et al., 2004). Therefore, we used a submaximal (80 µM) with co-application pH 5.8 solution to inhibit a large part, but not all of
the ASIC current. We observed little effect of amiloride on desensitization of ASIC current.
Fig. 3C demonstrates that amiloride only reduced the desensitization time constant of ASIC
currents from 0.83 ± 0.15 s to 0.72 ± 0.14 s (n = 9, p = 0.28). These results suggest that
diminazene inhibits ASIC currents via a distinct mechanism compared to amiloride and
implies that diminazene and amiloride represent different classes of ASIC channel
inhibitors.
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We also found that the facilitation of desensitization of these currents by diminazine was
dependent upon its concentration. The greatest change occurred with 1 µM diminazine
which changed the desensitization time constant from 1.7 ± 0.2 to 0.4 ± 0.1 s (n = 13, p <
0.01, Fig. 3D). Fig. 3D also suggests that the effect of diminazene increased when the initial
rate of desensitization of ASIC current was slower. This suggests that individual subtypes of
ASICs might have different sensitivities to diminazene as recombinant ASIC receptors
demonstrate substantially different rates of desensization.
As ASIC and ENaC proteins share considerable homology (Kellenberger and Schild, 2002),
we heterologously expressed ENaC channels in Xenopus oocytes and used two-electrode
voltage clamp techniques to test if diarylamidines block ENaC activities. Fig. 4A shows that
none of these four diarylamidines (DAPI, HSB, pentamidine and diminazene; n = 8 for
each) inhibit ENaC current in oocytes at a concentration of 100 µM. But at this
concentration DAPI (n = 5), diminazene (n = 5) and HSB (n = 5) blocked ASIC1a currents
in oocytes almost completely. For pentamidine (n = 5) a block of 77% on ASIC1a was
observed. These data indicate that diaryamidines act selectively on ASIC channel over
ENaC. Low pH stimuli induce action potentials and membrane depolarization by activating
ASICs (Baron et al., 2002). To determine whether diminazene could inhibit this acidNeuropharmacology. Author manuscript; available in PMC 2013 December 03.
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induced increase in excitability, we performed current-clamp recordings from cultured
hippocampal neurons. Fig. 4B shows that pH 6 markedly depolarized neurons and evoked a
train of action potentials. Application of diminazene (10 µM) dramatically attenuated the pH
6-induced depolarization and excitation (n = 7) illustrating that this medicinal compound
could be used to attenuate acid-induced over-excitation by inhibiting ASIC activities.
Diminazene (10 µM) itself had little effect on firing frequency (Fig. 4C, n = 4), implying
that it is unlikely to affect voltage-gated ion currents underlying the generation of action
potentials in these neurons.
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We next heterologously expressed individual ASIC subtypes in CHO cells and assessed the
effect of diminazene on ASIC currents mediated by individual ASIC subunits. We first
tested the effect of diminazene on the ASIC1a current. A preliminary concentration–
response analysis revealed an IC50 of ~ 3 µM for the inhibition of the ASIC1a current by
diminazene (n = 2, not shown). Therefore, in the subsequent experiments, 3 µM diminazene
was used to compare its effect on ASIC currents mediated by ASIC1a, -1b, -2a, and -3
subunits. Addition of diminazene (3 µM) in both the conditioning solution (pH 7.4) and the
low pH solutions dramatically reduced the amplitude of ASIC1a, -1b, -2a, and -3 currents
(Fig. 5). Following a 2 min perfusion of diminazene, ASIC1a current was inhibited by 39 ±
3.8%; ASIC1b by 92 ± 0.5%; ASIC2a by 51 ± 6.1%; and ASIC3 by 74 ± 0.6%. The
inhibition of the ASIC currents by diminazene was completely reversible (Fig. 5). Therefore,
diminazene most potently blocks ASIC1b, an ASIC subunit exclusively expressed in
sensory neurons (Chen et al., 1998).
3.3. Docking diarylamidines onto the crystal structure of ASICs suggests a potential
common binding region

NIH-PA Author Manuscript

DAPI, HSB and pentamidine and diminazene are linear divalent cations which are
determined by their amidine groups at both ends, with variable bulk (i.e. benzene rings) on
the outer edge of the molecule. They are semi-symmetric with two diarylamidines connected
by molecular bridges of varying length and composition. They could probably bind to the
same domain of ASICs due to their similar structural pattern. We therefore used in-silicon
“Patchdock” analysis to study where these compounds bind to ASIC by making use of
recently solved cASIC1 crystal structure (Gonzales et al., 2009). Patchdock can provide
computational analysis and predict the docking of ligands to their receptors, yielding a
variety of binding possibilities with scores ranking from high to low. First we analyzed
binding possibilities using one subunit of ASIC1 structure. Although there are different
binding possibilities for each individual inhibitor, all four diarylamidines docked onto one
common region (Fig. 6A). In addition, docking possibilities for these common regions
generated the highest scores, suggesting this region might likely be the binding domain.
Patchdock analysis implied that these diarylamidines bind to a small groove in the surface of
cASIC1 crystal, which is formed by part of the beta-ball domain and the palm domain. The
bottom part of the groove is formed mostly by hydrophobic amino acids (Fig. 6B), which
thereby create a hydrophobic micro-environment. The dumbbell-shaped diarylamidine
blockers fit well into this groove. The hydrophobic groove is consistent with the structural
properties of diarylamidines which are mostly hydrophobic, except for their charged
diamidine termini, composed of aromatic rings connected with hydrophobic linkage. The top
of the groove constitutes a narrow gate (with an opening of 4.9 Å) controlled by K205 and
D184, which probably allow the longitudinal diarylamidines (length varying from 12 to 19
Å) to bind into the groove from one angle (Fig. 6B). To avoid over-simplification of the
patchdock based on single subunit, we also performed patchdock computations using the full
trimeric ASIC1 crystal structures. Consistently these computations also suggested that
diarylamidines likely bind to the same region, although the probability scores were not as
high as that using single subunit. Fig. 6C shows that diminazene docks onto the full trimeric
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channel. Docking experiments suggested a potential common binding region of
diarylamidines on ASIC. Nevertheless, we could not rule out that diarylamidines might bind
to other domains.

4. Discussion
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In this study we first report that diarylamidines inhibit ASIC currents with high potencies
compared to known ASIC inhibitors such as amiloride. Diarylamidines are a large family of
synthetic compounds. Currently this chemical family has more than 30 members and its
family number is rapidly increasing (Baraldi et al., 2004). Diarylamidines have been widely
used for the treatment of protozoan diseases such as trypanosomiasis and leishmaniasis since
1930s (Baraldi et al., 2004; Mishra et al., 2007; Rosenthal, 2007). We tested a few agents
and report that four agents potently inhibit ASIC currents and it is conceivable that other
diarylamidines would inhibit ASIC activities. Pentamidine is the best known member of the
diarylamidines because of its activity against trypanosomatid protozoans and Pneumocystis
jirovecii. Hydroxystilbamidine had been used in the treatment of nonprogressive
blastomycosis of the skin and other mycoses (Hermans and Keys, 1983). Diminazene is
commonly used in veterinary medicine for the treatment of trypanosomiasis in domestic
livestock (Baraldi et al., 2004; Kinabo, 1993). DAPI is widely used as a fluorescence marker
for chromosomal DNA, a classic minor groove binder at A/T sequence (Baraldi et al., 2004).
DAPI demonstrates strong anti-trypanosome activity but its clinical use as an anti-protozoal
agent has been limited due to its strong undesirable cytotoxic side effects (Baraldi et al.,
2004). Other agents like pentamidine also demonstrate significant cytotoxicity but it remains
in use clinically (Rosenthal, 2007). The anti-protozoan mechanism of diarylamidines is not
yet clearly known. Proposed anti-protozoan mechanisms include DNA-binding to the minor
groove (Wilson et al., 2005), because DAPI, diminazene, pentamidine, and HSB all bind to
the minor groove of DNA.
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As the ASIC crystal structure has been solved (Gonzales et al., 2009), the “Patchdock”
computation allowed us to dock DAPI, diminazene, HSB and pentamidine, respectively to
the ASIC1 crystal structure and analyze possible binding domain of these diarylamidines.
Our analysis suggests that these four compounds likely bind to one region of ASICs and that
region is located at the beta-ball and palm domain. We also experimented with nafamostat
using Patchdock analysis and found nafamostat also docks onto the same region as
diarylamidines (not shown), supporting the hypothesis that these similar di-cationic
compounds share the same binding region on ASICs. Nevertheless, docking analysis has its
shortcoming. It only suggests several binding possibilities and it cannot explicitly indicate a
binding site. Therefore we cannot rule out the possibility that other binding regions exist.
Indeed, some other possible binding sites are suggested by the patchdock, for example, one
possible binding site is a cavity, formed by residues S252, E255, L262, S305, I306, N367,
V368, T369 and R370. But these sites are less likely than the one we have shown, because
not all compounds dock there. To definitely confirm the binding site, however, mutagenesis
experiments are required.
Our data show that diminazene influences ASIC desensitization while amiloride does not. In
addition, diarylamidines are structurally distinct from amiloride (Table 1). Diarylamidines
constitute a novel class of non-amiloride ASIC blockers. DAPI, diminazene, HSB and
pentamidine have been tested on ENaC activities respectively and we found these four
compounds (up to 100 µM) were ineffective on ENaC, indicating that DAPI, diminazene,
HSB and pentamidine are selective blockers for ASIC over ENaC. These results are in line
with the very weak inhibition (IC50: ~ 1 mM) on ENaC by nafamostat (Ugawa et al., 2007).
Diarylamidines thereby provide alternative pharmacological tools for ASIC study.
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The rank order of apparent inhibitory potencies among the diamidine compounds we tested
was diminazene > HSB > DAPI > pentamidine. Pentamidine is connected by a linker that
confers structural flexibility (see Table 1) and this may explain its relatively low affinity for
inhibition of ASICs. The other three compounds appear to have more rigid structures than
pentamidine. Each of these four compounds inhibited ASIC currents, indicating that the
linker in each of these diamidines can be variable, while the amidine group linked with an
aromatic moiety appears to be essential. Supporting evidence comes from the negative result
using netropsin. This compound is also a di-cation that binds to the minor groove of DNA
but the charged ends do not directly mount on the aromatic moiety (Table 1) (Nelson et al.,
2007). The observation that netropsin failed to inhibit ASICs also suggests that not all DNAbinding divalent cationic agents will inhibit ASICs and even DNA-binding agents need
additional structural components in order to bind to ASICs. Furthermore, the weak
inhibition by imidocarb suggests that the presence of two charged freely moving termini
contribute to the efficient of binding to ASICs.
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Tissue acidosis is known to contribute to nociception (Steen et al., 1995) and accumulating
evidence has suggested that ASICs participate in acid-induced pain under pathological
conditions like inflammation and ischemia (Deval et al., 2008; Xu and Duan, 2009). Thus,
ASICs expressed in sensory neurons provide new targets for designing blockers that relieve
pain. Although efforts have been made to identify potent ASICs blockers, these efforts have
met with limited success (Dube et al., 2005; Ugawa et al., 2007; Kuduk et al., 2009b). We
have identified diarylamidines as potent ASICs blockers. Further structure–function studies
of these compounds may identify even more potent or subtype-specific inhibitors of ASICs.
For example, diminazene display higher inhibitory potency against the currents mediated by
ASIC1b, a sensory neuron-specific ASIC subunit (Chen et al., 1998) and ASIC3, a subunit
associated primarily with pain sensation (Sluka et al., 2003). Therefore, diminazene may
have potential to be used as effective agents for pain suppression. Furthermore,
accumulating evidence documents that ASIC channels are emerging as potential therapeutic
targets for the alleviation of ischemic stroke (Xiong et al., 2008,, 2004), multiple sclerosis
(Friese et al., 2007), anxiety or depression (Sluka et al., 2009; Wemmie et al., 2006). Our
study indicates that diarylamidines are leading compounds for future chemical design and
screening of potent ASIC inhibitors, and that diarylamidines or similar agentsmay be
developed as therapeutic agents to cure ASIC-involved diseases.
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Fig. 1.

Chemicals that have no effect, or only have partial effect, on ASIC activities in cultured
hippocampal neurons. A. Carbenoxolone (200 µM) did not inhibit ASIC activities. Left,
exemplary current trace overlay; right, bar graph of relative current without and with
carbenxolone. n = 4, p = 0.1. B. Netropsin (100 µM) did not inhibit ASIC activities. Left,
exemplary current trace overlay; right, bar graph showing relative current without and with
netropsin, n = 6, p = 0.24. C. Synthalin (200 µM) inhibited 30 ± 2% (n = 6, p < 0.01) of
ASIC activities. Left, exemplary current trace overlay; right, bar graph of relative current
without and with synthalin. D. Imidocarb (200 µM) inhibited 42 ± 7% (n = 5, p < 0.05) of
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ASIC currents. Left, exemplary current trace overlay; right, bar graph showing relative
current without and with imidocarb.
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Fig. 2.

Pentamidine, HSB and DAPI reversibly blocked ASIC activities in cultured hippocampal
neurons. A. Pentamidine inhibited ASIC current. Left, representative current traces; right,
concentration response. IC50: 38 ± 11 µM, n = 4. B. HSB inhibited ASIC activities in
cultured hippocampal neurons. Left, exemplary current traces; right, concentration response.
IC50: 1.5 ± 0.6 µM, n = 5. C. DAPI inhibited ASIC current. Left, representative current
traces; right, concentration response. IC50, 2.8 ± 0.7 µM, n = 4.
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Fig. 3.

Diminazene potently inhibited ASIC current in cultured hippocampal neurons. A.
Diminazene blocked ASIC. Left, representative ASIC current traces with and without
diminazene. ASIC current was evoked by application of pH 5.8; right, concentration
response of ASIC inhibition by diminazene. IC50: 0.28 ± 0.11 µM, n = 6. B. Co-applied
diminazene promoted the closure of ASIC currents. Left, representative current traces. Coapplied diminazene (3 µM) with pH 5.8 drastically accelerated the decay of desensitization
of AISC currents; right, statistics of desensitization time constant; control 1.6 ± 0.3 s; with
diminazene, 0.4 ± 0.1 s and washout 1.6 ± 0.4 s, n = 6, p < 0.001. C. Sub-maximal
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concentration of amiloride (80 µM, co-applied with pH 5.8) did not accelerate the
desensitization of ASIC current. Left, current trace examples; right, statistics of
desensitization time constant with and without amiloride. D. Sub-maximal concentrations of
diminazene (by perfusion) significantly accelerated the desensitization of ASIC current.
Statistics of desensitization time constant of ASIC at the absence or presence of 3 µM, 1 µM,
0.3 µM and 0.1 µM diminazene, respectively.
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Fig. 4.

Diarylamidines failed to block oocyte-expressing ENaC channels. A. DAPI, HSB,
pentamidine and diminazene (at 100 µM, respectively) did not inhibit ENaC activities.
ENaC channels were blocked by perfusion of 10 µM amiloride, brief washout of amiloride
(indicated by white bars) revealed ENaC activities. Top, after control, diarylamidines (black
bars) were applied before and during amiloride-washout; Bottom, bar graph of relative
currents of ENaC with and without diarylamidines. ENaC activities were not significantly
affected by DPAI (0.98 ± 0.04, n = 8, p = 0.69), by HSB (1.02 ± 0.04, n = 8, p = 0.55), by
pentamidine (1.02 ± 0.03, n = 8, p = 0.57) or by diminazene (1.11 ± 0.05, n = 8, p = 0.06).
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B. Diminazene attenuated low pH-induced neuronal excitability. Application of pH 5.8 to
neuron caused action potentials and sustained depolarization; addition of diminazene (10
µM) markedly attenuated membrane depolarization. n = 7. C. Current-clamp recording.
Action potentials were elicited by current injection. Application of diminazene (10 µM) did
not affect action potentials. n = 4.
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Fig. 5.

Diminazene inhibited ASIC currents mediated by individual ASIC subunit expressed in
CHO cells. Diminazene (3 µM) reversibly inhibited the ASIC currents mediated by
homomeric ASIC1a (A), homomeric ASIC1b (B), homomeric ASIC2a (C), and homomeric
ASIC3 channels (D) expressed in CHO cells. E. Summary bar graph showing the inhibition
of the ASIC1a, 1b, 2a, or 3 current by 3 µM diminazene. ASIC1a current was reduced by 39
± 3.8% (n = 7, p < 0.01), ASIC1b current by 92 ± 0.5% (n = 8, p < 0.01), ASIC2a current by
51 ± 6.1% (n = 8, p < 0.01), and ASIC3 current by 74 ± 0.6% (n = 7, p < 0.01), respectively.
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Fig. 6.

Docking diarylamidines onto cASIC1 crystal structure. A. Diminazene, HSB, DAPI and
pentamidine commonly docked to a groove-shaped domain onto ASIC1. Crystal structure of
ASIC1 and ASIC blockerswere uploaded into the server, respectively and dock computation
was performed by the pacthdock server (http://bioinfo3d.cs.tau.ac.il/PatchDock/). B.
Enlargement of the binding domain with diminazene bound. Individual amino acids in the
binding domain as well as their positions in protein sequence were shown. The bottom part
of the groove was formed by residues F175, K186, T197, F198, N199, A200, G201, and
L208. The hydrophobic bottom part of the groove is large so that it accommodates sizevariation of these blockers. Charged amino acids D184 and K205 control the upper
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restrictive entrance of the binding region. C. Steric side-view of ASIC channel. Diminazene
docked onto the same place in the trimeric channel. Three subunits of ASIC channel are
shown in distinct colors. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
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Table 1

Comparing known ASIC inhibitors with diarylamidines.
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Name

Formula

Inhibition (potency)
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Amiloride

Hallmark blocker

Diclofenac

Weak inhibition

Nafamostat

Inhibition

A-317567

Inhibition

Pentamidine

Inhibition 38 ± 11 µM

DAPI

Strong inhibition 2.8 ± 0.7 µM

Diminazene

Strong inhibition 0.3 ± 0.1 µM

Hydroxystilbamidine

Strong inhibition 1.5 ± 0.6 µM
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Inhibition (potency)
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Imidocarb

Inhibit 42 ± 7% at 200 µM

Synthalin

Inhibit 29 ± 3% at 200 µM

Netropsin

No inhibition at 200 µM
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